Pfizer stock at EUR 25.41 with USD 161.8 billion market cap

Published on 10/12/2026 at 15:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pfizer stock stood at EUR 25.41 on October 12, 2026 during trading. The US quote was USD 28.39 and market value USD 161.8 billion.

Key points in brief

Pfizer stock was at EUR 25.41 at Lang & Schwarz on October 12, 2026 at 3:38 p.m. CEST.
The US quote was USD 28.39 on the NYSE, while market capitalization stood at USD 161.8 billion.
Pfizer traded at a trailing P/E ratio of 37.50, with third-quarter results scheduled for November 3, 2026.
JPMorgan raised its target from USD 28.00 to USD 30.00 while keeping a Neutral rating.

Editorialfoto eines Trading-Floors mit Sektor-Charts, Symbolbild für den Aktienhandel von Pfizer Inc — Börsen-Editorialfoto vom Trading-Floor mit Pharma-Charts steht sinnbildlich für den Aktienhandel von Pfizer Inc., ISIN US7170811035, Illustration mit AI erstellt.

Pfizer Inc. (ISIN US7170811035) was trading at EUR 25.41 at Lang & Schwarz on October 12, 2026 at 3:38 p.m. CEST, while its NYSE quote stood at USD 28.39 at 9:46 a.m. ET. The euro quotation gives German investors the clearest same-day market reference, while the US listing anchors Pfizer's valuation in its home currency.

US quote and valuation

Pfizer's market capitalization was USD 161.8 billion on October 12, 2026. The trailing price-to-earnings ratio was 37.50 and the dividend yield was 6.00 percent, putting income and earnings valuation at the center of the market picture.

Pfizer operates as a global biopharmaceutical company across medicines, vaccines, biologics and biosimilars. Its portfolio spans oncology, vaccines, inflammation and immunology, internal medicine and rare diseases, with contract manufacturing adding a separate business line.

Comparison with peers

Pfizer Inc.: P/E 37.50, market capitalization USD 161.8 billion

AbbVie Inc. (NYSE, USD): plus 0.64 percent, P/E 78.44, market capitalization USD 491.6 billion

Merck & Co., Inc. (NYSE, USD): plus 0.25 percent, P/E 116.73, market capitalization USD 360.5 billion

Analyst targets and calendar

Yahoo Finance reported on October 10, 2026 that JPMorgan moved its Pfizer target from USD 28.00 to USD 30.00 while retaining a Neutral rating. The same report said Bank of America raised its target from USD 27.00 to USD 29.00, Cantor Fitzgerald from USD 27.00 to USD 28.00 and Scotiabank from USD 30.00 to USD 33.00.

Pfizer has scheduled its third-quarter 2026 results and analyst conference call for November 3, 2026. The company announced the date in a September 22, 2026 release, which says the performance report will be issued that morning and the call will begin at 10:00 a.m. EST.

Pfizer stock before November 3

The next dated corporate event is the third-quarter report on November 3, 2026. That date gives the current EUR 25.41 quotation a defined calendar marker, while the USD 161.8 billion market value and the 37.50 P/E ratio frame the valuation investors will reassess when the report arrives.

The further course of trading is shown by the continuously updated real-time quote of Pfizer stock.